Literature DB >> 12738347

The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic.

Sharon L Walsh1, Thomas Eissenberg.   

Abstract

This paper will review clinical pharmacology studies on buprenorphine, a mixed opioid agonist-antagonist currently approved as a treatment for opioid dependence. The focus is on studies characterizing buprenorphine's pharmacodynamic actions, including its safety, abuse liability, withdrawal suppression and withdrawal precipitation capacity, physical dependence potential, cross-tolerance and duration of action as well as a review of the pharmacological profile of buprenorphine/naloxone combinations. The findings from these clinical pharmacology studies are synthesized and presented in a framework designed to (1) inform clinicians about the advantages and disadvantages of buprenorphine as an opioid maintenance agent, and (2) provide information about dosing procedures that may optimize the use of buprenorphine in the clinic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738347     DOI: 10.1016/s0376-8716(03)00056-5

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  55 in total

Review 1.  Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.

Authors:  Daniel P Alford; Peggy Compton; Jeffrey H Samet
Journal:  Ann Intern Med       Date:  2006-01-17       Impact factor: 25.391

2.  The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  Drug Alcohol Depend       Date:  2006-09-12       Impact factor: 4.492

3.  Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Authors:  James Rosado; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2007-05-22       Impact factor: 4.492

4.  Pharmacologically assisted treatment of opioid-dependent youth.

Authors:  Anna Pecoraro; Marc Fishman; Michelle Ma; Gvantsa Piralishvili; George E Woody
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

Review 5.  The role of human drug self-administration procedures in the development of medications.

Authors:  S D Comer; J B Ashworth; R W Foltin; C E Johanson; J P Zacny; S L Walsh
Journal:  Drug Alcohol Depend       Date:  2008-04-24       Impact factor: 4.492

6.  Buprenorphine maintenance therapy in opioid-addicted health care professionals returning to clinical practice: a hidden controversy.

Authors:  Heather Hamza; Ethan O Bryson
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

7.  Medication-assisted treatment for opioid addiction: methadone and buprenorphine.

Authors:  Andrew J Saxon; Yih-Ing Hser; George Woody; Walter Ling
Journal:  J Food Drug Anal       Date:  2013-12       Impact factor: 6.079

8.  Organizational implementation of evidence-based substance abuse treatment in racial and ethnic minority communities.

Authors:  Erick G Guerrero; Amy He; Ahraemi Kim; Gregory A Aarons
Journal:  Adm Policy Ment Health       Date:  2014-11

9.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

Review 10.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.